CD73 | ApexOnco - Clinical Trials news and analysis

“The insights provided by the analysts are great”

Director New Product Planning

Morphosys

Click here for more information

Data insights Trial results

11 March 2026

The company has ditched a trial of drebuxelimab plus ivonescimab.

Trial results

17 September 2025

Data insights

13 December 2024

Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.

Deals

26 September 2024

Deals

9 July 2024

Deals

23 April 2024

Subscribe to CD73

Recent Quick take